The regulatory ZFAS1/miR-150/ST6GAL1 crosstalk modulates sialylation of EGFR via PI3K/Akt pathway in T-cell acute lymphoblastic leukemia

Qianqian Liu, Hongye Ma, Xiuhua Sun, Bing Liu, Yang Xiao, Shimeng Pan, Huimin Zhou, Weijie Dong, Jia LiJournal of Experimental & Clinical Cancer Research 2019 · DOI

Introduction

T-cell acute lymphoblastic leukemia (T-ALL) remains a clinical challenge due to the high rate of relapse driven by multidrug resistance (MDR). While the role of altered glycosylation in cancer is well-documented, the specific regulatory mechanisms linking non-coding RNAs to surface glycan changes have been poorly understood. This study identifies a novel regulatory circuit—the ZFAS1/miR-150/ST6GAL1 axis—that modulates the sialylation of the Epidermal Growth Factor Receptor (EGFR), thereby activating pro-survival signaling pathways in resistant leukemia cells.

Glycan Profiling and the Role of ST6GAL1

To understand the biochemical basis of resistance, researchers compared drug-sensitive (CR) and adriamycin-resistant (CR/A) T-ALL cell lines using MALDI-TOF mass spectrometry. The analysis revealed significant differences in $N$-glycan composition, specifically an upregulation of sialylated glycoforms in the resistant cells.

Figure 1: MALDI-TOF MS spectra and relative signal intensity of N-glycans in drug-sensitive (CR) and resistant (CR/A) T-ALL cell lines.

Among the enzymes responsible for these changes, the sialyltransferase ST6GAL1 emerged as a critical player. Experimental knockdown of ST6GAL1 was found to restore drug sensitivity and increase apoptosis in resistant cells, while its overexpression conferred resistance to sensitive cells.

The ZFAS1/miR-150/ST6GAL1 Regulatory Axis

The study mapped a complex "competing endogenous RNA" (ceRNA) network. The long non-coding RNA (lncRNA) ZFAS1 acts as a molecular "sponge" for miR-150. Under normal conditions, miR-150 suppresses the expression of ST6GAL1. However, in MDR T-ALL cells, elevated levels of ZFAS1 sequester miR-150, effectively upregulating ST6GAL1.

This increase in ST6GAL1 leads to enhanced $\alpha$2,6-sialylation of EGFR. This modification stabilizes the receptor and triggers the PI3K/Akt pathway, a major survival cascade that allows cancer cells to bypass the lethal effects of chemotherapy.

Clinical Validation and Patient Outcomes

The relevance of this axis was confirmed in clinical samples from 46 T-ALL patients. ST6GAL1 expression was significantly higher in patients with multidrug resistance compared to those without.

Figure 4: mRNA expression of sialyltransferases in cell lines and patient samples, including the correlation between ST6GAL1 expression and overall survival.

Importantly, patients with high ST6GAL1 expression exhibited significantly poorer overall survival ($P = 0.0249$), highlighting the enzyme's potential as both a prognostic biomarker and a therapeutic target.

Conclusion

This research provides a comprehensive map of how non-coding RNAs regulate the "sugar coating" of cancer cells to drive drug resistance. By targeting the ZFAS1/miR-150/ST6GAL1 axis or the downstream PI3K/Akt pathway, clinicians may eventually be able to overcome multidrug resistance in T-ALL patients. Future work will focus on identifying the upstream triggers for ZFAS1 and developing effective delivery systems for RNA-based therapies.

Summary updated

Abstract

In the original publication of this article [1], there is a mistake in Fig. 4E.
BibTeX
@article{liu2019regulatory,
  author = {Qianqian Liu and Hongye Ma and Xiuhua Sun and Bing Liu and Yang Xiao and Shimeng Pan and Huimin Zhou and Weijie Dong and Jia Li},
  title = {{The regulatory ZFAS1/miR-150/ST6GAL1 crosstalk modulates sialylation of EGFR via PI3K/Akt pathway in T-cell acute lymphoblastic leukemia}},
  journal = {Journal of Experimental \& Clinical Cancer Research},
  year = {2019},
  doi = {10.1186/s13046-019-1208-x},
}
Figure